Precigen Q2 Earnings Call Highlights

Precigen NASDAQ: PGEN reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy's August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP.

Related Symbols 1

P PGEN PGEN

Source: MarketBeat

Visit Source

0 0 0

Comment

Important Notice: More than 48 hours have passed since this news or analysis was published. Due to the volatility of financial markets, some of the information or data presented may no longer be valid or reflect current market conditions. Please verify the information again before making any trading or investment decisions.

Comments

No comments yet

Be the first person to comment on this news item.

Category Stock

Source MarketBeat

Published 1 month ago

Likes 0

Comments 0

Shares 0

News ID #491

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.